Regenerx Biopharmaceuticals Inc., of Rockville, Md., said a paper published in Investigative Ophthalmology and Visual Science describes Thymosin beta 4's (TB4) effects on dry eye syndrome and its potential value for the treatment of other ophthalmic disorders.